Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.contributor | Universidade Estadual Paulista (Unesp) | - |
Autor(es): dc.contributor | General Hospital of Shenyang Military Command | - |
Autor(es): dc.creator | Lima, Talles Bazeia [UNESP] | - |
Autor(es): dc.creator | Santos, Lívia Alves Amaral [UNESP] | - |
Autor(es): dc.creator | Nunes, Hélio Rubens de Carvalho [UNESP] | - |
Autor(es): dc.creator | Silva, Giovanni Faria [UNESP] | - |
Autor(es): dc.creator | Caramori, Carlos Antonio [UNESP] | - |
Autor(es): dc.creator | Qi, Xingshun | - |
Autor(es): dc.creator | Romeiro, Fernando Gomes [UNESP] | - |
Data de aceite: dc.date.accessioned | 2022-02-22T00:28:21Z | - |
Data de disponibilização: dc.date.available | 2022-02-22T00:28:21Z | - |
Data de envio: dc.date.issued | 2020-12-11 | - |
Data de envio: dc.date.issued | 2020-12-11 | - |
Data de envio: dc.date.issued | 2019-11-30 | - |
Fonte completa do material: dc.identifier | http://dx.doi.org/10.1038/s41598-019-55603-y | - |
Fonte completa do material: dc.identifier | http://hdl.handle.net/11449/199800 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/11449/199800 | - |
Descrição: dc.description | Despite the high prevalence of osteoporosis in liver cirrhosis, the indication of bisphosphonates for patients with esophageal varices has been avoided due to risk of digestive mucosal damage. Therefore, this study aimed to evaluate the safety profile of risedronate treatment for patients with osteoporosis, liver cirrhosis and esophageal varices with low risk of bleeding. A total of 120 patients were allocated into two groups according to their bone mineral density measured by dual-energy X-ray absorptiometry. In the intervention group, 57 subjects with osteoporosis received oral risedronate at 35 mg weekly plus daily calcium and vitamin D supplementation. In the control group, 63 subjects with osteopenia received only calcium and vitamin D. The groups received the treatment for one year and underwent surveillance endoscopies at six and 12 months, as well as a control dual-energy X-ray absorptiometry after a 12-month follow-up. The study received Institutional Review Board approval. The groups had not only comparable Model for End-stage Liver Disease score and esophageal varices degree, but also similar incidence of digestive adverse effects. A significant improvement was achieved in the intervention group in the lumbar spine T score (p < 0.001). The results suggest that risedronate may be safely used in liver cirrhosis and esophageal varices with low bleeding risk under endoscopic surveillance, thus allowing bone mass recovery. | - |
Descrição: dc.description | Internal Medicine Department Gastroenterology Division – São Paulo State University (UNESP) Botucatu Medical School | - |
Descrição: dc.description | Public Health Department São Paulo State University (UNESP) Botucatu Medical School | - |
Descrição: dc.description | General Hospital of Shenyang Military Command | - |
Descrição: dc.description | Internal Medicine Department Gastroenterology Division – São Paulo State University (UNESP) Botucatu Medical School | - |
Descrição: dc.description | Public Health Department São Paulo State University (UNESP) Botucatu Medical School | - |
Idioma: dc.language | en | - |
Relação: dc.relation | Scientific Reports | - |
???dc.source???: dc.source | Scopus | - |
Título: dc.title | Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial | - |
Tipo de arquivo: dc.type | livro digital | - |
Aparece nas coleções: | Repositório Institucional - Unesp |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: